Non-Executive Director – Biotechnology – Oncology – Ref.: JVM161018T
Our Client is developing treatments for the deadliest of all cancers, pancreatic cancer. The lead therapeutic product is designed to neutralise gastrin, a known growth factor and risk factor for gastrointestinal cancers like pancreatic cancer, oesophageal cancer and related Barrett’s oesophagus, a precancerous condition and colon and gastric cancers.
Over $230M has been invested. Over 1100 patients have participated in clinical trials with no serious adverse effects to prove that hormone neutralization therapy is efficacious.
They are seeking an experienced NED to join the board that brings expertise in biotechnology, ideally cancer knowhow and has a background of previously being an NED for a listed company.